News about Quality / GMP

Lupin's Nagpur Facility Receives EIR from U.S. FDA

Lupin's Nagpur Facility Receives EIR from U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Nagpur, India facility. The inspection for the facility was carried out by the U.S. FDA between January 6, 2020 and January 10, 2020

Quality / GMP | 13/04/2020 | By Darshana


We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology